Amneal Pharmaceuticals (AMRX) Receivables - Other (2017 - 2026)

Amneal Pharmaceuticals' Receivables - Other history runs 10 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 152.87% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (up 152.87% YoY), while the FY2025 annual figure was $5.3 million, up 183.46% from the prior year.
• Receivables - Other was $6.2 million for Q1 2026 at Amneal Pharmaceuticals, up from $5.3 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $100.0 million in Q2 2022 to a low of $1.8 million in Q4 2022.
• Historically, Receivables - Other has averaged $14.9 million across 5 years, with a median of $5.3 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other surged 4184.3% in 2022, then plunged 96.64% in 2023.
• A 5-year view of Receivables - Other shows it stood at $1.8 million in 2022, then soared by 445.25% to $9.9 million in 2023, then tumbled by 81.19% to $1.9 million in 2024, then soared by 183.46% to $5.3 million in 2025, then rose by 16.43% to $6.2 million in 2026.
• The last three Receivables - Other figures came in at $6.2 million (Q1 2026), $5.3 million (Q4 2025), and $24.2 million (Q3 2025), per Business Quant data.